{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:45:39Z","timestamp":1765039539855},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>A significant reduction in CA 125 postoperative serum levels was observed after risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers. In contrast to previous studies, where control groups were absent, we conducted a prospective study including also a screening only group (RSSO refusal) and a group having previously undergone RRSO.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Consecutive BRCA1 and BRCA2 mutation carriers, not hysterectomised, &gt;35 years old and with completed childbearing, were recruited. Some women had previously undergone RRSO (previous RRSO group). The others, who had either chosen RRSO (actual RRSO group) or screening only (screening only group), were enrolled (patient-preference trial). A prospective evaluation (basal and 6-month) of CA 125 and CEA (control biomarker) was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study consisted of 116 women, 44.8% BRCA1 and 55.2% BRCA2 mutation carriers (n = 25 in the previous RRSO group, n = 29 in the actual RRSO group, n = 62 in the screening only group). For all subjects, we observed a 6-month decrease in CA 125 (\u22127.8%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003), which was significantly linked only to endometriosis history (odds ratio 1.4; 95% confidence interval 1.1\u20131.8; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002). Between different groups, we recorded a non-significantly different decrease in CA 125. CEA showed a 6 months significant increase (+15.4%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001), which was similar between groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The decrease in CA 125 in BRCA mutation carriers after RRSO was only partially associated with surgery, depending also on a physiological decline: this is extremely important in their longitudinal monitoring for the prevention of ovarian cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cej.0000000000000606","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T11:00:24Z","timestamp":1591700424000},"page":"350-356","source":"Crossref","is-referenced-by-count":7,"title":["The reduction of CA 125 serum levels in BRCA 1\/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study"],"prefix":"10.1097","volume":"29","author":[{"given":"Giovanni","family":"Grandi","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Del Savio","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Sammarini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[{"name":"Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Piombino","sequence":"additional","affiliation":[{"name":"Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Facchinetti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma.","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IGC.0000000000001134","article-title":"Dynamic prediction of outcome for patients with ovarian cancer: application of a joint model for longitudinal cancer antigen 125 values.","volume":"28","author":"Cao","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10689-013-9697-9","article-title":"Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.","volume":"13","author":"Chen","year":"2014","journal-title":"Fam Cancer"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3802\/jgo.2014.25.1.51","article-title":"A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer.","volume":"25","author":"Chiang","year":"2014","journal-title":"J Gynecol Oncol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000479155","article-title":"Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the Modena Study Group Cohort Study.","volume":"93","author":"Cortesi","year":"2017","journal-title":"Oncology"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2015.03.047","article-title":"HE4 in the differential diagnosis of ovarian masses.","volume":"446","author":"Granato","year":"2015","journal-title":"Clin Chim Acta"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/scbi.1998.0119","article-title":"The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.","volume":"9","author":"Hammarstr\u00f6m","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cncr.31211","article-title":"Peritoneal carcinomatosis after risk-reducing surgery in BRCA1\/2 mutation carriers.","volume":"124","author":"Harmsen","year":"2018","journal-title":"Cancer"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","article-title":"Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.","volume":"2","author":"Kabawat","year":"1983","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/humrep\/deh890","article-title":"Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas.","volume":"20","author":"Kitawaki","year":"2005","journal-title":"Hum Reprod"},{"key":"R12-20230902","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"key":"R13-20230902","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"key":"R14-20230902","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.1200\/JCO.2005.01.6642","article-title":"Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.","volume":"23","author":"Menon","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-20230902","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0015-0282(98)00355-0","article-title":"The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis.","volume":"70","author":"Mol","year":"1998","journal-title":"Fertil Steril"},{"key":"R17-20230902","first-page":"489","article-title":"Factors influencing serum CA125II levels in healthy postmenopausal women.","volume":"10","author":"Pauler","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R18-20230902","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1158\/1940-6207.CAPR-10-0402","article-title":"Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.","volume":"4","author":"Skates","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"R19-20230902","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.","volume":"76","author":"Skates","year":"1995","journal-title":"Cancer"},{"key":"R20-20230902","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-15-2750","article-title":"Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.","volume":"23","author":"Skates","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R21-20230902","doi-asserted-by":"crossref","first-page":"301","DOI":"10.23736\/S0026-4806.19.06091-9","article-title":"Hereditary ovarian cancers: state of the art.","volume":"110","author":"Toss","year":"2019","journal-title":"Minerva Med"},{"key":"R22-20230902","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/gme.0b013e3181ecfb51","article-title":"Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?","volume":"18","author":"van Altena","year":"2011","journal-title":"Menopause"},{"key":"R23-20230902","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0090-8258(90)90130-D","article-title":"Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer.","volume":"36","author":"Zurawski","year":"1990","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T01:09:31Z","timestamp":1693616971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000606","relation":{},"ISSN":["0959-8278"],"issn-type":[{"value":"0959-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}